Regulatory GuideNovember 18, 2026 · 18 min read · VEMERIX

Which Registration Track Fits Your Medical Device in Uganda?

Uganda’s NDA names three device registration tracks, but its overview and its detailed checklist draw them differently. Match the exact product and approval before you rely on one.

Market EntryMedical Device Regulation
Abstract illustration of a pathway passing checklist, search and verification markers toward a row of gates, representing evidence checks before a Uganda device filing and shipment

What decision does this guide support?

This guide is for regulatory and procurement staff at a foreign manufacturer of sterile single-use surgical devices, working with a proposed Ugandan distributor or applicant. It covers one pre-filing decision. Which existing approval should be put forward for an NDA registration track? Which records must be requested from the manufacturer? When should a launch plan or first commercial order wait for a written answer from Uganda?

The NDA’s detailed registration guidance for this product group is written for surgical instruments and appliances, its term for the device category handled here.2 This guide does not cover medicines, IVD-specific programmes, veterinary products or clinical investigations. It is desk research checked on 18 November 2026. It does not assign a track or a Ugandan risk class to any real product, and it is not a regulatory determination. The applicant’s confirmed position with the NDA is the deciding record.

How do the NDA overview and the 2020 checklist describe each track?

Two NDA texts describe the tracks. The Medical Devices web page gives a one-line definition of each track.1 The 2020 Guidelines on Registration of Surgical Instruments and Appliances list what each track’s application must contain.2 Both NDA documents refused automated retrieval when we checked, so we compared the track wording with a consultancy page that reproduces the overview and the per-track checklists in detail.3 An independent 2023 study of device innovators in Uganda describes the same structure. Marketing authorisation applications are reviewed under three tracks depending on whether prior international approval exists, and approvals from recognised reference markets such as IMDRF countries can be leveraged through an expedited review.4

TrackNDA overview wording2020 checklist framingEvidence the checklist namesConfirm before filing
Track 1Products registered and approved in IMDRF countriesAppliances licensed in an IMDRF member country. Asks for a notarized licence copy from an “IMDRF founding member country” and lists Australia, Canada, the EU, Japan and the USNotarized licence copy; a market-specific marketing permit (for example CE marking for the EU or a 510(k) letter for the US); a quality-system certificate for the issuing marketDoes the decision name this exact model, size range, sterile pack and manufacturing site, and is it current?
Track 2Products prequalified by WHO or registered in SRA countriesAppliances not licensed in one of the listed IMDRF countriesQuality-system certificate (for example ISO 13485); notarized licence copy (for example CE marking)Which non-listed licence or WHO record will the NDA accept for this product, and does a CE certificate place it in Track 1 or Track 2?
Track 3Products with no prior approval by a reference agency (SRA, IMDRF country or WHO prequalification)Appliances that do not have certificationManufacturer’s declaration of conformity; summary of preclinical design verification and validationIs Track 3 open for this product’s Ugandan class, and what further evidence will reviewers ask for?
Table 1. Uganda’s three device registration tracks in the NDA overview and the 2020 checklist

Source: Overview wording: NDA Medical Devices page, compared with its reproduction by OMC Medical. Checklist framing and evidence: NDA 2020 surgical-instrument guideline as reproduced by OMC Medical. The last column is an editorial recommendation, not an NDA requirement.

Every track’s checklist also asks for the same core items. These are a covering letter in which the applicant attests that all information is true and correct, product details, manufacturer details, evidence of repeat sales in the country of manufacture, an appropriate number of product samples where practicable, and a completed submission checklist.3 The repeat-sales item matters for export-only products. If a device is made in one country but sold only abroad, ask the applicant early what evidence will satisfy that line.

The checklist also shows its age. It still lists legacy quality-system document names alongside ISO 13485.3 Do not treat those as current file types. Ask the applicant which certificate the NDA expects now.

Where do the two NDA descriptions disagree?

The overview and the checklist are short and long versions of one framework, but they draw the track boundaries differently, and those differences decide where many real files land. Three gaps need a written answer before a launch plan relies on a track.

IMDRF countries versus five named markets

The overview ties Track 1 to “IMDRF countries.”1 The checklist asks for a licence from an IMDRF founding member country and prints only five markets: Australia, Canada, the EU, Japan and the US.3 The current IMDRF Management Committee is larger. It consists of regulatory agencies from Australia, Brazil, Canada, China, the European Union, Japan, Russia, Singapore, South Korea and the United States.6 A registration from Brazil, China, Russia, Singapore or South Korea fits the overview’s literal wording but not the checklist’s list. Neither the buyer nor the manufacturer should resolve that by assumption. Ask the applicant to obtain the NDA’s position for the specific decision being offered.

WHO and SRA status versus “not licensed in a listed country”

The overview defines Track 2 by WHO prequalification or registration in an SRA country.1 The checklist defines it by the absence of a listed IMDRF licence, and names a quality-system certificate and a licence such as CE marking as the evidence.3 Neither text, as checked, publishes a current list of the SRA countries it means. CE marking also appears twice. It is the EU marketing permit under Track 1 and an example licence under Track 2.3 The same CE certificate could therefore be read either way. Which way may depend on its scope, the issuing body and the device it actually names. Get the reading confirmed rather than choosing the faster-sounding track.

No prior approval versus no certification

The overview places products with no reference approval in Track 3.1 The checklist describes Track 3 as the track for appliances without certification, supported by a declaration of conformity and preclinical verification and validation summaries.3 A product with a valid ISO 13485 certificate but only a home-market registration outside the listed markets sits between those definitions. The detailed guideline also links certification to risk class. It describes a possible exemption from recognised-country certification for Class A devices after NDA examination, and expects recognised-country or CE certification for higher classes.2 Track 3 should therefore not be planned as a universal fallback for a Class B, C or D sterile device.

What must match between the quoted product and the reference decision?

Registration is product-specific. The reproduced guidance calls for a separate, complete electronic dossier for each surgical instrument or appliance, group or family. The registration file asks for all certificates issued by an assessment body as evidence of approval or clearance. It also asks for the manufacturing process, including the sterilization method and the facilities with the steps performed at each, a manufacturing flowchart and a letter of authorization.3 A foreign decision helps a Uganda track only if it can be reconciled with those fields for the model you will ship.

WHO’s advice to procurement agencies offers a useful standard. When buying from WHO’s prequalification lists, agencies should use the most current list edition. They should confirm that the manufacturer will supply the product exactly as described in the WHO Public Report, including the product code and regulatory version, and that it is made at the site WHO assessed and inspected.5 The NDA does not publish that rule for its tracks. But the same matching discipline is a sensible way to test any approval offered as Track 1 or Track 2 evidence.

FieldRead from the quotationRead from the reference decisionIf they differ
Legal manufacturerName and address on the labelName and address on the decision or certificateStop. Ask whether a different legal manufacturer or private label is involved
Brand, model and catalogue codesEvery code quotedCodes or device description namedList uncovered codes; request coverage evidence or remove them from the filing
Size range and variantsSizes and adult or paediatric typesSizes and types coveredTreat uncovered sizes as outside the reference evidence
Sterile configuration and packSterile or non-sterile; primary packConfiguration named or impliedA non-sterile or bulk decision does not cover a sterile blister version without justification
Sterilization method and siteMethod and site on the label or technical fileMethod and site in the decision or its annexRequest the validation record that links them
Manufacturing sites and stepsSites in the manufacturing flowchartSites in the decision or certificate scopeAsk which site is covered for which step
Decision statusDate offered by the supplierNumber, issue date, expiry and current statusDo not file an expired or superseded decision
Ugandan classClass proposed by the applicantNot taken from the foreign decisionConfirm under Ugandan rules; a foreign class is a different system
Proposed trackTrack named by the applicantWho confirmed it, and in what recordHold commercial commitments until it is confirmed in writing
Table 2. One-SKU worksheet: reconcile the quote with the reference decision before proposing a track

Source: Editorial worksheet built from the dossier fields in the NDA guidance as reproduced by OMC Medical and WHO procurement checks. It is not an NDA form.

How does the Ugandan risk class change the file?

The NDA uses four risk classes. Class A is low risk (for example surgical retractors and tongue depressors). Class B is low to moderate (hypodermic needles, suction equipment). Class C is moderate to high (lung ventilators, bone fixation plates). Class D is high risk (heart valves, implantable defibrillators).3 The class is assigned under Ugandan rules. A Class II label from China’s NMPA or another regulator belongs to a different system and should not be copied into a Uganda application.

Class and track are two separate axes. The track describes the approval evidence you already hold. The class drives the dossier contents. The reproduced guidance lists a Class A file as Form 7, a letter of authorization, IFU and catalogues or brochures, labels, sterilization methods where applicable and an ISO 13485 certificate. Class B, C and D files instead list device details, a summary of technical documentation, labels, an essential-requirements checklist and an ISO 13485 certificate, again with Form 7 and the letter of authorization.3 A sterile single-use device that may fall in Class B or above should therefore be planned with a technical-documentation summary, whatever track it ends up in.

Registration is also not a one-off cost. The reproduced guidance ties continued validity to an annual retention fee. For products the NDA designates high risk, it also requires annual post-marketing surveillance reports.3 The 2026 Act likewise keeps a registered device on the register each financial year on payment of the prescribed fee.7 Build both into the distributor agreement.

Which Ugandan records must exist before a commercial shipment?

The NDA’s overview handles product registration, the licensing of outlets and import permits as separate subjects.1 The reproduced guidance states that companies must be licensed before manufacturing, importing or supplying devices, that devices must be registered before distribution, and that company registration documents go in with the file for the first product.3 These are three records, often with three different names on them, and each answers a different question.

RecordWhose name it carriesWhat it answersWhat it does not answerSuggested hold point
Product registration certificateThe registration holder, for the product as registeredHas the NDA registered this product?Whether a premises may deal in it, or whether a consignment may enterBefore commercial stock is ordered for Uganda
Premises (outlet) licenceThe local legal entity and its licensed premisesMay this entity deal in this category at this address?Whether a specific product is registeredBefore the distribution agreement takes effect
Import permitThe importer, for a stated consignmentMay this shipment enter Uganda?Whether the product is registered, if the permit is for samples or a special caseBefore dispatch
Table 3. Three Ugandan records that a distributor should verify separately

Source: Record types: NDA Medical Devices page and NDA guidance as reproduced by OMC Medical. Hold points are editorial recommendations for commercial planning, not NDA sequencing rules.

Samples need their own instruction. Each track’s checklist asks for an appropriate number of product samples where practicable.3 Before sending any, get the applicant’s written instruction on quantity, variants, recipient and the import route. Sending registration samples does not show that the product is registered. Once the 2026 Act’s device provisions commence, the Authority may authorise importing an unlicensed device that it needs for registration, subject to conditions it sets.7 That is a specific authorisation, not a general exemption.

What changes when the 2026 Act commences?

The National Drug and Health Products Authority Act, 2026 (Act 5 of 2026) received assent on 29 April 2026. It was published in the Acts Supplement to the Uganda Gazette of 8 May 2026. Section 1 says the Act comes into force on a date the Minister appoints by statutory instrument, and allows different dates for different provisions. Section 119 repeals the National Drug Policy and Authority Act.7

The device provisions point to new regulations. Section 54 leaves device classification to regulations made under the Act. Section 55 bars manufacturing, distributing, importing, exporting or supplying a device unless it is registered, notified or listed. It also leaves the classes, conditions and categories of supplying businesses to regulations. Section 57 requires an import licence before a device is imported.7 Two savings provisions protect current files. Statutory instruments made under the old Act stay in force, so far as they are consistent with the new Act, until revoked. Licences issued and registrations made under the old Act remain valid for their duration, modified only to the extent they are inconsistent.7

We did not find a commencement instrument in our 18 November 2026 check. Until one is confirmed, the NDA’s existing track structure remains the working reference. New regulations could later redraw the tracks, the classes or the import licence. Ask the applicant which regime applies on the planned submission date, and recheck before each new filing.

Three hypothetical files and what each still needs

These scenarios are hypothetical. They describe no actual NDA application, classification or outcome, and none is a VEMERIX filing.

ScenarioEvidence offeredWhy it does not settle the trackNext request
A. Listed-market decision, different configurationA US 510(k) letter for a ring device described as non-sterile, bulk-packed. The quote is for a sterile, individually blistered versionTrack 1 evidence must cover the product filed. The sterile configuration, sterilization site and pack are not shown in the decisionA decision or documented justification covering the sterile configuration, plus the sterilization validation that links site and pack; NDA confirmation of track
B. WHO prequalification of another productA distributor cites WHO prequalification for circumcision devices in generalWHO matching is by product code, regulatory version and manufacturing site. Another manufacturer’s prequalified device is not evidence for this oneThe WHO list entry and Public Report naming this product, or drop WHO as Track 2 evidence
C. Non-listed IMDRF member plus QMS certificateA Chinese-made sterile device with NMPA registration, an ISO 13485 certificate and a CE statement on the brochureChina is outside the checklist’s five markets. The CE statement needs its certificate, issuing body, scope and validity. The overview and checklist could place the file in different tracksThe CE certificate and its device annex, the NMPA certificate, and a written NDA position on Track 1 versus Track 2
Table 4. Hypothetical Uganda files: evidence offered, gap and next request

Source: Hypothetical cases built on the NDA track wording (NDA overview and 2020 guidance as reproduced by OMC Medical), WHO procurement checks and the current IMDRF Management Committee roster.

In each case the worksheet sends the file back for one specific record rather than a vague “more documents.” For scenario B, our separate guide shows how to verify a WHO-prequalified circumcision device by product and version. For a regional comparison of reliance routes, see Kenya reliance and emergency authorization. If an application is later queried, the response discipline in our Ghana FDA device-query guide transfers well, although Ugandan procedure differs.

Pre-filing checklist for the manufacturer and the Ugandan applicant

  • The applicant has named the proposed Ugandan class and track for each model, and has recorded who at the NDA confirmed them and in what document.12
  • Each quoted catalogue code, size and pack appears in the reference decision offered, or the gap is listed with a justification or a removal decision.
  • A licence offered as Track 1 evidence comes from Australia, Canada, the EU, Japan or the US, or the NDA has confirmed in writing how it treats another IMDRF member’s decision.36
  • A CE certificate has been checked for its issuing body, device scope, manufacturing sites and validity, and the NDA’s reading of it (Track 1 or Track 2) is recorded.3
  • Any WHO prequalification cited names this product’s code, regulatory version and manufacturing site in the current list and Public Report.5
  • The class-specific dossier items are ready: Form 7, letter of authorization, labels, ISO 13485 certificate, and for Class B to D a technical-documentation summary and essential-requirements checklist.3
  • Evidence of repeat sales in the country of manufacture has been agreed with the applicant, especially for export-only products.3
  • Product registration, the applicant’s premises licence and the import permit are tracked as three records with their own holders and dates.1
  • Sample quantity, variants, recipient and import route are confirmed in writing before any sample ships.
  • The applicant has confirmed whether any part of the 2026 Act has commenced on the planned submission date.7

Where VEMERIX fits—and where due diligence still begins

VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care.

The VEMERIX circumcision device page describes a single-use ring with Adult and Children types and 14 size codes. It is ethylene-oxide sterilized and supplied in individual sterile blister packs. The page lists China’s NMPA Class II registration Lu Mech Reg. 20172020238 and a CE statement.8 Those are catalogue facts. They are not a Ugandan registration, a Ugandan class or a track decision, and this guide does not assign one. Our WHO prequalification check found that the device was not on the WHO list of prequalified male circumcision devices when we checked in September 2026, so WHO prequalification is not available as Track 2 evidence for it.

For a Uganda discussion, the useful next step is an exact-model technical pack rather than a brochure. Tell us the destination, the proposed size codes and pack, the intended Ugandan applicant and the reference decision you plan to rely on, through the VEMERIX contact page. The quality and regulatory information page describes the manufacturer’s quality documentation. The applicant’s confirmed NDA position remains the gate.

Frequently asked questions

Does IMDRF membership make an NMPA registration Track 1 evidence?

Not on its own. China sits on the current IMDRF Management Committee6, but the NDA checklist prints only Australia, Canada, the EU, Japan and the US for Track 1.3 Ask the applicant to obtain the NDA’s position before relying on it.

Can a WHO report for a different model support this product’s track?

No. WHO tells procurers to match the product code, regulatory version and manufacturing site to the assessed product.5 A report for another model, version or manufacturer does not transfer.

Is an ISO 13485 certificate enough for registration?

No. The checklist lists it as one document in the class-based dossier and as Track 2 evidence.3 It is a quality-system certificate, not a product authorisation.

Can a product without a reference approval always use Track 3?

Do not assume so. The checklist describes Track 3 for appliances without certification. The guideline also ties recognised-country or CE certification to classes above Class A.23 Confirm with the NDA before planning on it.

Does a product registration also cover the outlet or the import?

No. The NDA treats product registration, the licensing of outlets and import permits as separate permissions.1 Check each record, and the name on it, separately.

Has the 2026 Act already changed the tracks?

Not as far as we found. The Act comes into force by ministerial statutory instrument, and existing registrations and licences remain valid for their duration.7 We found no commencement instrument in our 18 November 2026 check. Recheck before filing.

Source scope and when to recheck

Sources checked 18 November 2026. The NDA’s Medical Devices page and its 2020 Revision 0 surgical-instrument guideline both refused automated retrieval at our check. Their track wording and per-track checklists were compared with a detailed consultancy reproduction and with a 2023 peer-reviewed study. Neither of those is an NDA ruling.1234 The IMDRF roster comes from the Singapore regulator’s page, last updated 7 November 2026.6 The Act text comes from the Gazette supplement.7

Recheck this guide when the NDA publishes a revised device or surgical-instrument guideline, when it changes the Track 1 reference markets, when a commencement instrument or device regulations under the 2026 Act appear, or when a product’s model, pack, legal manufacturer or manufacturing site changes.

Sources

  1. Uganda National Drug Authority (NDA), Medical Devices web page (undated; checked 18 November 2026). Registration tracks, licensing of outlets and import permits. The page refused automated retrieval at our check; its track wording was compared with the reproduction in source 3.
  2. Uganda National Drug Authority, Guidelines on Registration of Surgical Instruments and Appliances, Revision 0, 2020 (checked 18 November 2026). Track checklists, class-based dossier contents and certification conditions. The PDF refused automated retrieval at our check; per-track lists were compared with source 3.
  3. OMC Medical, Uganda Medical Device Registration: NDA Requirements (consultancy page reproducing the NDA track wording, per-track checklists, class table, dossier contents and registration-validity conditions; accessed 18 November 2026). A reproduction of the NDA source chain, not an independent authority.
  4. Nakandi BT, Muhimbise O, Djuhadi A, et al. Experiences of medical device innovators as they navigate the regulatory system in Uganda. Frontiers in Medical Technology. 2023;5:1162174. doi:10.3389/fmedt.2023.1162174 (accessed 18 November 2026).
  5. World Health Organization, Prequalification of in vitro diagnostics and male circumcision devices: Procurement agencies (accessed 18 November 2026). Current-list, product code, regulatory version and manufacturing-site checks.
  6. Health Sciences Authority, Singapore, International Medical Device Regulators Forum (IMDRF) page, last updated 7 November 2026 (accessed 18 November 2026). Current IMDRF Management Committee members.
  7. Republic of Uganda, National Drug and Health Products Authority Act, 2026 (Act 5 of 2026), Acts Supplement No. 4 to the Uganda Gazette No. 45 of 8 May 2026, copy archived by the Uganda Legal Information Institute (accessed 18 November 2026). Date of assent; sections 1, 54, 55, 57, 119 and 120.
  8. VEMERIX, Disposable Circumcision Ring — Adult & Pediatric, product page (accessed 18 November 2026). Catalogue description, variants, sterilization, packaging, NMPA registration and CE statement.

Talk to VEMERIX

VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care.